Free Access
Med Sci (Paris)
Volume 26, Number 4, Avril 2010
Page(s) 405 - 410
Section M/S revues
Published online 15 April 2010
  1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369 : 1641–57. [Google Scholar]
  2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126 : 1504–17. [Google Scholar]
  3. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8 : 458–66. [Google Scholar]
  4. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis as a prerequisite for IBD. Gut 2004; 53 : 1057. [Google Scholar]
  5. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105 : 16731–6. [Google Scholar]
  6. Moehle C, Ackermann N, Langmann T, et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med 2006; 84 : 1055–66. [Google Scholar]
  7. Hill KA, Wang KL, Stryker SJ, et al. Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer. Oncol Rep 2004; 11 : 951–6. [Google Scholar]
  8. Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24 : 202–8. [Google Scholar]
  9. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med 2009; 206 : 1883–97. [Google Scholar]
  10. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369 : 1627–40. [Google Scholar]
  11. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005; 129 : 50–65. [Google Scholar]
  12. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68 : 7010–7. [Google Scholar]
  13. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005; 307 : 734–8. [Google Scholar]
  14. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5 : 800–8. [Google Scholar]
  15. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 2003; 278 : 5509–12. [Google Scholar]
  16. Bamias G, Sugawara K, Pagnini C, Cominelli F. The Th1 immune pathway as a therapeutic target in Crohn’s disease. Curr Opin Investig Drugs 2003; 4 : 1279–86. [Google Scholar]
  17. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005; 206 : 296–305. [Google Scholar]
  18. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52 : 65–70. [Google Scholar]
  19. Leung-Theung-Long S, Guerder S. Les cellules Th17 : une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008; 24 : 972–6. [Google Scholar]
  20. Peyrin-Biroulet L, Parmentier-Decrucq E, Branche J, Desreumaux P. L’IL-23R, un nouveau gène de susceptibilité dans les maladies inflammatoires chroniques intestinales. Med Sci (Paris) 2007; 23 : 250–2. [Google Scholar]
  21. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007; 51 : 1139–47. [Google Scholar]
  22. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441 : 235–8. [Google Scholar]
  23. Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol 2008; 585 : 361–74. [Google Scholar]
  24. Keshavarzian A, Banan A, Farhadi A, et al. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut 2003; 52 : 720–8. [Google Scholar]
  25. Zimmerman NP, Vongsa RA, Wendt MK, Dwinell MB. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14 : 1000–11. [Google Scholar]
  26. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 : 515–23. [Google Scholar]
  27. Adams RJ, Heazlewood SP, Gilshenan KS, et al. IgG antibodies against common gut bacteria are more diagnostic for Crohn’s disease than IgG against mannan or flagellin. Am J Gastroenterol 2008; 103 : 386–96. [Google Scholar]
  28. Sendid B, Jouault T, Vitse A, et al. Anti-glycan antibodies establish an unexpected link between C. albicans and Crohn disease. Med Sci (Paris) 2009; 25 : 473–81 [Google Scholar]
  29. Wellcome Trust Case Control Consortium : Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447 : 661–78. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.